'Trk'-ish math: Loxo series B garners $24M for new cancer target
With $24 million of series B cash in hand, Loxo Oncology Inc. disclosed more about the pipeline's lead compound in a cancer effort than the company was willing when it garnered $33 million in the series A round last October.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter